Raymond James Financial Services Advisors’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $70.7M | Buy |
2,442,324
+26,369
| +1% | +$769K | 0.09% | 206 |
|
|
2024
Q2 | $67.6M | Buy |
2,415,955
+166,281
| +7% | +$4.58M | 0.1% | 201 |
|
|
2024
Q1 | $62.4M | Buy |
2,249,674
+175,979
| +8% | +$4.88M | 0.09% | 208 |
|
|
2023
Q4 | $59.7M | Sell |
2,073,695
-522,816
| -20% | -$15.8M | 0.1% | 200 |
|
|
2023
Q3 | $86.1M | Buy |
2,596,511
+25,008
| +1% | +$884K | 0.16% | 140 |
|
|
2023
Q2 | $94.3M | Buy |
2,571,503
+50,012
| +2% | +$1.95M | 0.17% | 138 |
|
|
2023
Q1 | $103M | Sell |
2,521,491
-43,123
| -2% | -$1.86M | 0.19% | 112 |
|
|
2022
Q4 | $131M | Sell |
2,564,614
-151,045
| -6% | -$7.24M | 0.26% | 81 |
|
|
2022
Q3 | $119M | Buy |
2,715,659
+629
| +0% | +$30.6K | 0.26% | 81 |
|
|
2022
Q2 | $142M | Sell |
2,715,030
-54,742
| -2% | -$2.79M | 0.31% | 70 |
|
|
2022
Q1 | $143M | Sell |
2,769,772
-110,696
| -4% | -$5.74M | 0.27% | 78 |
|
|
2021
Q4 | $170M | Buy |
2,880,468
+75,021
| +3% | +$3.72M | 0.32% | 64 |
|
|
2021
Q3 | $121M | Sell |
2,805,447
-59,427
| -2% | -$2.63M | 0.24% | 81 |
|
|
2021
Q2 | $112M | Buy |
2,864,874
+7,239
| +0.3% | +$282K | 0.23% | 90 |
|
|
2021
Q1 | $104M | Buy |
2,857,635
+207,500
| +8% | +$7.37M | 0.23% | 90 |
|
|
2020
Q4 | $97.6M | Buy |
2,650,135
+44,585
| +2% | +$1.64M | 0.24% | 87 |
|
|
2020
Q3 | $90.7M | Sell |
2,605,550
-152,997
| -6% | -$5.36M | 0.26% | 85 |
|
|
2020
Q2 | $85.6M | Sell |
2,758,547
-2,336,761
| -46% | -$79.4M | 0.27% | 75 |
|
|
2020
Q1 | $158M | Buy |
5,095,308
+338,103
| +7% | +$11.5M | 0.69% | 24 |
|
|
2019
Q4 | $177M | Buy |
4,757,205
+320,172
| +7% | +$11.4M | 0.57% | 29 |
|
|
2019
Q3 | $151M | Buy |
4,437,033
+180,793
| +4% | +$6.57M | 0.55% | 32 |
|
|
2019
Q2 | $175M | Buy |
4,256,240
+249,389
| +6% | +$9.9M | 0.67% | 23 |
|
|
2019
Q1 | $161M | Buy |
4,006,851
+309,271
| +8% | +$12.4M | 0.67% | 22 |
|
|
2018
Q4 | $153M | Buy |
3,697,580
+237,626
| +7% | +$9.86M | 0.81% | 21 |
|
|
2018
Q3 | $145M | Buy |
3,459,954
+197,517
| +6% | +$7.6M | 0.65% | 21 |
|
|
2018
Q2 | $112M | Buy |
3,262,437
+258,723
| +9% | +$8.84M | 0.57% | 26 |
|
|
2018
Q1 | $101M | Buy |
3,003,714
+254,629
| +9% | +$8.75M | 0.58% | 25 |
|
|
2017
Q4 | $94.5M | Buy |
2,749,085
+266,607
| +11% | +$9.09M | 0.59% | 24 |
|
|
2017
Q3 | $84.1M | Buy |
2,482,478
+114,139
| +5% | +$3.67M | 0.54% | 28 |
|
|
2017
Q2 | $75.5M | Buy |
2,368,339
+42,475
| +2% | +$1.34M | 0.52% | 29 |
|
|
2017
Q1 | $75.5M | Buy |
2,325,864
+260,970
| +13% | +$8.23M | 0.58% | 25 |
|
|
2016
Q4 | $63.6M | Buy |
2,064,894
+110,154
| +6% | +$3.36M | 0.53% | 29 |
|
|
2016
Q3 | $62.8M | Buy |
1,954,740
+110,019
| +6% | +$3.68M | 0.56% | 24 |
|
|
2016
Q2 | $61.6M | Buy |
1,844,721
+205,614
| +13% | +$6.56M | 0.6% | 24 |
|
|
2016
Q1 | $46.1M | Buy |
1,639,107
+237,248
| +17% | +$6.78M | 0.53% | 31 |
|
|
2015
Q4 | $42.9M | Buy |
1,401,859
+344,368
| +33% | +$10.8M | 0.5% | 30 |
|
|
2015
Q3 | $31.5M | Buy |
1,057,491
+811,073
| +329% | +$26M | 0.53% | 34 |
|
|
2015
Q2 | $7.84M | Sell |
246,418
-266,556
| -52% | -$8.69M | 0.56% | 33 |
|
|
2015
Q1 | $16.9M | Sell |
512,974
-20,122
| -4% | -$640K | 0.83% | 22 |
|
|
2014
Q4 | $15.8M | Buy |
533,096
+3,356
| +0.6% | +$96.2K | 0.82% | 18 |
|
|
2014
Q3 | $14.9M | Buy |
529,740
+3,914
| +0.7% | +$110K | 0.8% | 22 |
|
|
2014
Q2 | $14.8M | Sell |
525,826
-5,279
| -1% | -$150K | 0.88% | 20 |
|
|
2014
Q1 | $16.2M | Sell |
531,105
-10,347
| -2% | -$309K | 0.95% | 16 |
|
|
2013
Q4 | $15.7M | Sell |
541,452
-23,780
| -4% | -$692K | 0.97% | 18 |
|
|
2013
Q3 | $15.4M | Sell |
565,232
-14,255
| -2% | -$388K | 1.02% | 14 |
|
|
2013
Q2 | $15.4M | Buy |
+579,487
| New | +$16M | 0.45% | 43 |
|
Other funds holding PFE
Raymond James Financial Services Advisors's PFE Position: Q3 2024 in Review
Raymond James Financial Services Advisors increased its Pfizer (PFE) stake by 1.1% in Q3 2024, buying an estimated $769K and bringing the position to 2,442,324 shares worth $70.7M. The position accounts for 0.09% of the portfolio, ranked #206.
Raymond James Financial Services Advisors first reported a position in PFE in Q2 2013 and has held it in 46 quarters since. The position peaked at $177M in Q4 2019. 2,910 funds tracked by Wall St. Rank hold PFE as of Q3 2024.
- Raymond James Financial Services Advisors held 2,442,324 shares of Pfizer worth $70.7M as of Q3 2024.
- Raymond James Financial Services Advisors bought 26,369 Pfizer shares in Q3 2024, an estimated $769K.
- Pfizer made up 0.09% of Raymond James Financial Services Advisors's portfolio in Q3 2024, its #206 holding.
- Raymond James Financial Services Advisors first reported a position in Pfizer in Q2 2013 and has held it in 46 quarters since.
- Raymond James Financial Services Advisors's Pfizer position peaked at $177M in Q4 2019.
- 2,910 funds tracked by Wall St. Rank held Pfizer as of Q3 2024.
Based on Raymond James Financial Services Advisors's 13F filing for Q3 2024, filed 18 Oct 2024.